Does Ozempic lower cholesterol?

It improves cholesterol modestly. Across the semaglutide trials, total cholesterol fell about 5–7%, LDL ("bad") cholesterol about 5–8%, and triglycerides about 12–15%, with a small rise in HDL ("good") cholesterol. These are meaningful but modest changes, and they come largely from weight loss and dietary changes rather than a direct cholesterol-lowering action. It is a welcome bonus for people taking it for diabetes or weight — not a primary cholesterol treatment.

No. Statins lower LDL cholesterol by roughly 30–50% or more, versus about 5–8% with semaglutide — a very different magnitude. Ozempic is not approved to treat high cholesterol and does not replace a statin or other lipid-lowering therapy. If you need cholesterol treatment for cardiovascular risk, that remains a separate, proven part of your care; any lipid improvement from a GLP-1 is additive, not a substitute.

Most of the effect is a knock-on benefit of weight loss and improved metabolism, plus reduced triglyceride-rich particles as blood sugar and insulin resistance improve. The triglyceride reduction tends to be the largest of the lipid changes. Because it is largely weight-mediated, the size of the improvement varies with how much weight and metabolic change a person achieves.

Yes, unless your doctor tells you otherwise. The modest lipid improvement from a GLP-1 does not justify stopping a prescribed statin or other cholesterol medication, especially if you take it for cardiovascular risk. If your lipids improve on a GLP-1, your clinician may reassess — but that is a supervised decision, not a reason to stop treatment on your own.

Largely from the weight loss and the dietary changes that come with it — and that distinction matters practically. Weight-driven lipid improvements behave like weight-driven improvements generally do: they tend to recede if the weight returns. A statin's effect does not depend on your weight. So a better panel achieved during active weight loss means your risk profile improved while you are losing or maintaining, not that you have acquired a permanent lipid-lowering therapy — which is the reasoning behind why clinicians rarely withdraw a statin on that basis.

LDL cholesterol is the main treatment target for cardiovascular risk reduction, and non-HDL cholesterol — total minus HDL — is useful because it captures all the atherogenic particles in one figure. Triglycerides respond strongly to weight, alcohol and carbohydrate intake. Raising HDL has not proven to be a useful drug target on its own, despite its "good cholesterol" reputation. Total cholesterol alone is the least informative, since it is a composite. Compare panels drawn under the same conditions — triglycerides in particular shift with recent food and alcohol.